Unknown

Dataset Information

0

MTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials.


ABSTRACT: We evaluated if standard hormonal therapy (HT) could be improved by the addition of mammalian target of rapamycin inhibitors (mTOR-I) in metastatic luminal breast cancer. A meta-analysis on 4 phase II-III randomized clinical trials was performed. Pooled hazard ratio (HR) for progression free survival (PFS)/ time to progression (TTP) was 0.62 in favor of mTOR-I+HT arm (95% confidence interval [CI] 0.55-0.70; p<0.0001). There was significant heterogeneity for PFS/TTP (Cochran's Q 32, p<0.0001, I2 index 90.6%). Pooled HR for overall survival (OS) was 0.84 in favor of the combination arm (95% CI 0.71-0.99; p=0.04). Heterogeneity was not significant (Cochran's Q 4.47, p=0.1, I2 index 55.3%). Pooled risk ratio (RR) for objective response rate (ORR) was 0.88 in favor of experimental arm (95% CI 0.85-0.91; p<0.0001). Heterogeneity was not significant (Cochran's Q 2.11, p=0.3, I2 index 5.2%). Adverse events (AEs), in particular those of grade 3-4, mostly occurred in mTOR-I+HT arm. Combination therapy of HT plus mTOR-I improves the outcome of metastatic luminal breast cancer patients. Our results provide evidence of a class-effect of these targeting molecules.

SUBMITTER: Rotundo MS 

PROVIDER: S-EPMC5053632 | biostudies-other | 2016 May

REPOSITORIES: biostudies-other

altmetric image

Publications

mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials.

Rotundo Maria Saveria MS   Galeano Teresa T   Tassone Pierfrancesco P   Tagliaferri Pierosandro P  

Oncotarget 20160501 19


We evaluated if standard hormonal therapy (HT) could be improved by the addition of mammalian target of rapamycin inhibitors (mTOR-I) in metastatic luminal breast cancer. A meta-analysis on 4 phase II-III randomized clinical trials was performed. Pooled hazard ratio (HR) for progression free survival (PFS)/ time to progression (TTP) was 0.62 in favor of mTOR-I+HT arm (95% confidence interval [CI] 0.55-0.70; p<0.0001). There was significant heterogeneity for PFS/TTP (Cochran's Q 32, p<0.0001, I2  ...[more]

Similar Datasets

| S-EPMC8645913 | biostudies-literature
| S-EPMC8287214 | biostudies-literature
| S-EPMC7812178 | biostudies-literature
| S-EPMC6993232 | biostudies-literature
| S-EPMC4095689 | biostudies-literature
| S-EPMC7844919 | biostudies-literature
| S-EPMC10439209 | biostudies-literature
| S-EPMC5698336 | biostudies-literature
| S-EPMC4227311 | biostudies-literature
| S-EPMC4124146 | biostudies-literature